“Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s442. Accessed May 16, 2025. https://skin.dermsquared.com/skin/article/view/3141.